β-Arrestin-2 interaction and internalization of the human P2Y 1 receptor are dependent on C-terminal phosphorylation sites

Molecular Pharmacology

Volumn 76, Issue 6, 2009, Pages 1162-1171

  Reiner, Susanne ^a   Ziegler, Nicole ^a   Leon, Catherine ^b   Lorenz, Kristina ^a   Von Hayn, Kathrin ^a   Gachet, Christian ^b   Lohse, Martin J ^a   Hoffmann, Carsten ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 2; PROTEIN KINASE C; PURINERGIC P2Y1 RECEPTOR; YELLOW FLUORESCENT PROTEIN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN HEK293; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION;

ARRESTINS; CALCIUM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CATALYTIC DOMAIN; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; KIDNEY; MICROSCOPY, CONFOCAL; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE C; RECEPTORS, PURINERGIC P2;

EID: 73149107282     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.060467     Document Type: Article

References (38)

1. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, and Weisman GA (2006) International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58:281-341.
2. Baurand A, Eckly A, Bari N, Léon C, Hechler B, Cazenave JP, and Gachet C (2000) Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemost 84:484-491.
3. Baurand A, Eckly A, Hechler B, Kauffenstein G, Galzi JL, Cazenave JP, Léon C, and Gachet C (2005) Differential regulation and relocalization of the platelet P2Y receptors after activation: a way to avoid loss of hemostatic properties? Mol Pharmacol 67:721-733.
4. Burnstock G (2006) Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 58:58-86.
5. Choi RC, Simon J, Tsim KW, and Barnard EA (2008) Constitutive and agonistinduced dimerizations of the P2Y1 receptor: relationship to internalization and scaffolding. J Biol Chem 283:11050-11063.
6. Clark RB and Rich TC (2003) Probing the roles of protein kinases in g-protein-coupled receptor desensitization. Mol Pharmacol 64:1015-1017.
7. Desai S, April H, Nwaneshiudu C, and Ashby B (2000) Comparison of agonistinduced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration. Mol Pharmacol 58:1279-1286.
8. Ding Z, Tuluc F, Bandivadekar KR, Zhang L, Jin J, and Kunapuli SP (2005) Arg333 and Arg334 in the COOH terminus of the human P2Y1 receptor are crucial for Gq coupling. Am J Physiol Cell Physiol 288:C559-C567.
9. 2+ signaling in astrocytes. J Neurosci 23:4437-4444.
10. Fam SR, Paquet M, Castleberry AM, Oller H, Lee CJ, Traynelis SF, Smith Y, Yun CC, and Hall RA (2005) P2Y1 receptor signaling is controlled by interaction with the PDZ scaffold NHERF-2. Proc Natl Acad Sci U S A 102:8042-8047.
11. Ferguson SS (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53:1-24.
12. Ferguson SS (2007) Phosphorylation-independent attenuation of GPCR signalling. Trends Pharmacol Sci 28:173-179.
13. Gachet C (2006) Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 46:277-300.
14. Gurevich VV and Gurevich EV (2006) The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol Ther 110:465-502.
15. 2+ and cAMP in single cells. Sci STKE 2006:pl6.
16. Hardy AR, Conley PB, Luo J, Benovic JL, Poole AW, and Mundell SJ (2005) P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood 105:3552-3560.
17. Ho SN, Hunt HD, Horton RM, Pullen JK, and Pease LR (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51-59.
18. Hoffmann C, Gaietta G, Bünemann M, Adams SR, Oberdorff-Maass S, Behr B, Vilardaga JP, Tsien RY, Ellisman MH, and Lohse MJ (2005) A FlAsH-based FRET approach to determine G protein-coupled receptor activation in living cells. Nat Methods 2:171-176.
19. Hoffmann C, Moro S, Nicholas RA, Harden TK, and Jacobson KA (1999) The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes. J Biol Chem 274:14639-14647.
20. Hoffmann C, Ziegler N, Reiner S, Krasel C, and Lohse MJ (2008) Agonist-selective, receptor-specific interaction of human P2Y receptors with β-arrestin-1 and -2. J Biol Chem 283:30933-30941.
21. Jacobson KA, Jarvis MF, and Williams M (2002) Purine and pyrimidine (P2) receptors as drug targets. J Med Chem 45:4057-4093.
22. Jiang Q, Guo D, Lee BX, Van Rhee AM, Kim YC, Nicholas RA, Schachter JB, Harden TK, and Jacobson KA (1997) A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor. Mol Pharmacol 52:499-507.
23. Jones BW and Hinkle PM (2008) Arrestin binds to different phosphorylated regions of the thyrotropin-releasing hormone receptor with distinct functional consequences. Mol Pharmacol 74:195-202.
24. Jost CA, Reither G, Hoffmann C, and Schultz C (2008) Contribution of fluorophores to protein kinase C FRET probe performance. Chembiochem 9:1379-1384.
25. Krasel C, Bunemann M, Lorenz K, and Lohse MJ (2005) β-Arrestin binding to the β2-adrenergic receptor requires both receptor phosphorylation and receptor activation. J Biol Chem 280:20029528- 20029535.
26. Krasel C, Zabel U, Lorenz K, Reiner S, Al-Sabah S, and Lohse MJ (2008) Dual role of the β2-adrenergic receptor C terminus for the binding of β-arrestin and receptor internalization. J Biol Chem 283:31840-31848.
27. Lazarowski ER, Homolya L, Boucher RC, and Harden TK (1997) Direct demonstration of mechanically induced release of cellular UTP and its implication for uridine nucleotide receptor activation. J Biol Chem 272:24348-24354.
28. Lefkowitz RJ and Shenoy SK (2005) Transduction of receptor signals by betaarrestins. Science 308:512-517.
29. Liu Q, Dewi DA, Liu W, Bee MS, and Schonbrunn A (2008) Distinct phosphorylation sites in the SST2A somatostatin receptor control internalization, desensitization, and arrestin binding. Mol Pharmacol 73:292-304.
30. Lohse MJ (1993) Molecular mechanisms of membrane receptor desensitization. Biochim Biophys Acta 1179:171-188.
31. Lorenz K, Lohse MJ, and Quitterer U (2003) Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 426:574-579.
32. Moro S, Guo D, Camaioni E, Boyer JL, Harden TK, and Jacobson KA (1998) Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem 41:1456-1466.
33. Mundell SJ, Jones ML, Hardy AR, Barton JF, Beaucourt SM, Conley PB, and Poole AW (2006a) Distinct roles for protein kinase C isoforms in regulating platelet purinergic receptor function. Mol Pharmacol 70:1132-1142.
34. Mundell SJ, Luo J, Benovic JL, Conley PB, and Poole AW (2006b) Distinct clathrincoated pits sort different G protein-coupled receptor cargo. Traffic 7:1420-1431.
35. Tobin AB (2008) G-protein-coupled receptor phosphorylation: where, when and by whom. Br J Pharmacol 153 (Suppl 1):S167-S176.
36. Tulapurkar ME, Zündorf G, and Reiser G (2006) Internalization and desensitization of a green fluorescent protein-tagged P2Y nucleotide receptor are differently controlled by inhibition of calmodulin-dependent protein kinase II. J Neurochem 96:624-634.
37. Vishnivetskiy SA, Raman D, Wei J, Kennedy MJ, Hurley JB, and Gurevich VV (2007) Regulation of arrestin binding by rhodopsin phosphorylation level. J Biol Chem 282:32075-32083.
38. von Kügelgen I (2006) Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 110:415-432.